NRAS and cancer: To address whether this effect was unique to KRAS-mutant human cancer cells, PIP5K1A expression was similarly reduced by Cas9-mediated gene inactivation, as confirmed by immunoblot analysis, with three separate PIP5K1A sgRNAs in the HRAS-mutant human cancer cell lines HN30 and T24 (Fig. 5b) and in the NRAS-mutant human cancer cell lines SW1271, NCI-H1299, SK-MEL-2, and TYKNU (Fig. 5c).